+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

  • PDF Icon

    Report

  • 190 Pages
  • May 2022
  • Region: Global
  • Arizton
  • ID: 5591817
UP TO OFF until Aug 31st 2022
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.

SEGMENT ANALYSIS

  • Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
  • The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
  • Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.

Market Segmentation by Drug Class

  • Corticosteroids
  • Kinase Inhibitors
  • Calcineurin Inhibitors
  • TNF-Alpha Inhibitors
  • Other Class of Drugs

Market Segmentation by Treatment Type

  • GVHD Prophylaxis
  • Chronic GVHD
  • Acute GVHD

Market Segmentation by Gender Type

  • Males
  • Females

GEOGRAPHIC ANALYSIS
  • The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.

Market Segmentation by Geography

  • North America
  • US
  • Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • APAC
  • China
  • Japan

VENDOR ANALYSIS

  • With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.

Key Players

  • Incyte
  • Pharmacyclics
  • Bristol-Myers Squibb
  • JCR Pharmaceuticals Co., Ltd.
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • MaaT Pharma
  • XeniKos
  • Medac GmbH
  • Mesoblast
  • Kadmon
  • Jazz Pharmaceuticals
  • Gsk
  • Novartis
  • Syndax Pharmaceuticals Inc

Other Prominent Vendors

  • Neovii
  • ElsaLys Biotech
  • Mallinckrodt
  • Regimmune
  • Roche
  • Altrubio
  • CTTQ
  • Equillium
  • Janssen (johnson & johnson)
  • ASC Therapeutics
  • MSD
  • Genentech
  • Sun Pharma
  • Mink Therapeutics
  • Pluristem

The Report Covers The following details:

  • Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
  • Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
  • Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
  • Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
  • In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
  • Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
  • Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space

Table of Contents

Chapter - 1 Gvhd Overview
  • Graft Versus Host Disease - An Overview

Chapter - 2 Gvhd Epidemiology & Overview
  • 8Mm Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • 8Mm Comparative Analysis of Hsct & Allogeneic - Hsct
  • 8Mm Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • 8Mm Comparative Analysis of Incidence of Agvhd & Cgvhd
  • Us Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • Us Comparative Analysis of Hsct & Allogeneic - Hsct
  • Us Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • Us Comparative Analysis of Incidence of Agvhd & Cgvhd
  • China Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • China Comparative Analysis of Hsct & Allogeneic - Hsct
  • China Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • China Comparative Analysis of Incidence of Agvhd & Cgvhd
  • Germany Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • Germany Comparative Analysis of Hsct & Allogeneic - Hsct
  • Germany Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • Germany Comparative Analysis of Incidence of Agvhd & Cgvhd
  • Japan Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • Japan Comparative Analysis of Hsct & Allogeneic - Hsct
  • Japan Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • Japan Comparative Analysis of Incidence of Agvhd & Cgvhd
  • France Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • France Comparative Analysis of Hsct & Allogeneic - Hsct
  • France Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • France Comparative Analysis of Incidence of Agvhd & Cgvhd
  • Italy Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • Italy Comparative Analysis of Hsct & Allogeneic - Hsct
  • Italy Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • Italy Comparative Analysis of Incidence of Agvhd & Cgvhd
  • UK Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • UK Comparative Analysis of Hsct & Allogeneic - Hsct
  • UK Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • UK Comparative Analysis of Incidence of Agvhd & Cgvhd
  • Spain Historic & Projected Volume of Hsct & Allogeneic - Hsct
  • Spain Comparative Analysis of Hsct & Allogeneic - Hsct
  • Spain Historic & Projected Volume of Incidence of Agvhd & Cgvhd
  • Spain Comparative Analysis of Incidence of Agvhd & Cgvhd

Chapter - 3 Gvhd Market Size & Overview
  • 8Mm Historic & Projected Revenue of Gvhd
  • 8Mm Historic & Projected Revenue of Gvhd Snapshot
  • 8Mm Major Approved & Off-Label Drugs in Gvhd
  • 8Mm Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • Us Historic & Projected Revenue of Gvhd
  • Us Historic & Projected Revenue of Gvhd Snapshot
  • Us Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • China Historic & Projected Revenue of Gvhd
  • China Historic & Projected Revenue of Gvhd Snapshot
  • China Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • Germany Historic & Projected Revenue of Gvhd
  • Germany Historic & Projected Revenue of Gvhd Snapshot
  • Germany Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • Japan Historic & Projected Revenue of Gvhd
  • Japan Historic & Projected Revenue of Gvhd Snapshot
  • Japan Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • France Historic & Projected Revenue of Gvhd
  • France Historic & Projected Revenue of Gvhd Snapshot
  • France Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • Italy Historic & Projected Revenue of Gvhd
  • Italy Historic & Projected Revenue of Gvhd Snapshot
  • Italy Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • UK Historic & Projected Revenue of Gvhd
  • UK Historic & Projected Revenue of Gvhd Snapshot
  • UK Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class
  • Spain Historic & Projected Revenue of Gvhd
  • Spain Historic & Projected Revenue of Gvhd Snapshot
  • Spain Historic & Projected Revenue Segmentation by Treatment Type, Gender Type & Drug Class

Chapter - 4 Gvhd Marketed Drugs Overview
  • Gvhd Marketed Drugs - An Overview
  • Gvhd Marketed Drugs - Summary

Chapter - 5 Gvhd Pipeline Drugs Overview
  • Gvhd Pipeline Drugs - An Overview
  • Gvhd Pipeline Drugs - Snapshot
  • Gvhd Pipeline Drugs Overview & Snapshot - by Disease Type
  • Gvhd Pipeline Drugs Overview & Snapshot - by Development Phase
  • Gvhd Pipeline Drugs Overview & Snapshot - by Route of Administration
  • Gvhd Pipeline Drugs Overview & Snapshot - by Mechanism of Action
  • Gvhd Pipeline Drugs Overview & Snapshot - by Molecule Type
  • Gvhd Pipeline Drugs Overview & Snapshot - by Geography Type

Chapter - 6 Gvhd Clinical Trials Overview
  • Gvhd Clinical Trials Overview Snapshot
  • Gvhd Clinical Trials Overview - by Recruitment Status
  • Gvhd Clinical Trials Overview - by Product Type
  • Gvhd Clinical Trials Overview - by Route of Administration
  • Gvhd Clinical Trials Overview - by Molecule Type
  • Gvhd Clinical Trials Overview - by Geography Type

Chapter - 7 Gvhd Market Dynamics
  • Gvhd Treatment Market Drivers
  • Gvhd Treatment Market Constraints
  • Gvhd Treatment Market Trends

Chapter - 8 Gvhd Competitive Landscape
  • Gvhd Competitive Landscape - Marketed Drugs
  • Unmet Needs & Strategic Recommendations
  • Competitive Assessment of Off-Label & Late-Stage Drugs
  • Key Company Profiles
  • Competitive Scenario of Gvhd Treatment Market
  • Other Prominent Company Profiles
  • Key Company Overviews
  • Gvhd Competitive Landscape - Pipeline Drugs
  • Key Emerging Company Profiles
  • Key Emerging Company Overviews
  • Other Prominent Company Profiles

Chapter - 9 Gvhd Miscellaneous
  • Key Tentative Drug Approvals Timeline
  • Key Regulatory Designations
  • Key Milestones
  • Deals & Collaborations
  • Inactive/Discontinued/Dormant Products

Chapter - 10 Appendix
  • About Arizton
  • Research Methodology
  • List of Abbreviations

Companies Mentioned

  • Incyte
  • Pharmacyclics
  • Bristol-Myers Squibb
  • JCR Pharmaceuticals Co., Ltd.
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • MaaT Pharma
  • XeniKos
  • Medac GmbH
  • Mesoblast
  • Kadmon
  • Jazz Pharmaceuticals
  • Gsk
  • Novartis
  • Syndax Pharmaceuticals Inc
  • Neovii
  • ElsaLys Biotech
  • Mallinckrodt
  • Regimmune
  • Roche
  • Altrubio
  • CTTQ
  • Equillium
  • Janssen (johnson & johnson)
  • ASC Therapeutics
  • MSD
  • Genentech
  • Sun Pharma
  • Mink Therapeutics
  • Pluristem

Methodology


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...